Top Markets
Coin of the day
ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc.

ZVSA
Rangering i aksjer #38791
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical... ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Aksjekurs
$0.099
Markedsverdi
$801.50K
Endring (1 dag)
0.00%
Endring (1 år)
-34.44%
Land
US
Handel ZyVersa Therapeutics, Inc. (ZVSA)

Kategori

P/B-forhold for ZyVersa Therapeutics, Inc. (ZVSA)
P/B-forhold per 2026 TTM: 0
Ifølge ZyVersa Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for ZyVersa Therapeutics, Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE